Verified Nov 2026
Other
·

New York, New York
·
Since 2002
Intra-Cellular Therapies is a biopharmaceutical company headquartered in New York, founded in 2002, with 500–1,000 employees and estimated revenue between $500 million and $1 billion. The company discovers and develops small-molecule treatments for central nervous system and neuropsychiatric disorders. Its approved product CAPLYTA treats schizophrenia and bipolar depression, while its pipeline addresses generalized anxiety disorder, Alzheimer's agitation, and Parkinson's disease. Johnson & Johnson acquired the company in 2025.
Intra-Cellular Therapies at a glance
Revenue
$500M-1B
Est. band
Employees
500-1,000
Founded
2002
Headquarters
New York, New York
Industries
Automotive
Electric Vehicles
Medical
Overview
Intra-Cellular Therapies is a biopharmaceutical company headquartered in New York, founded in 2002, with 500–1,000 employees and estimated revenue between $500 million and $1 billion. The company discovers and develops small-molecule treatments for central nervous system and neuropsychiatric disorders. Its approved product CAPLYTA treats schizophrenia and bipolar depression, while its pipeline addresses generalized anxiety disorder, Alzheimer's agitation, and Parkinson's disease. Johnson & Johnson acquired the company in 2025.
At a glance
Attribute | Detail |
|---|---|
Founded | 2002 |
Headquarters | New York, New York |
Employees | 500-1,000 |
Revenue | $500M-1B (estimated) |
What Intra-Cellular Therapies makes
The company employs a proprietary CNSProfile technology platform to validate and select drug candidates, and has built a pipeline of investigational small-molecule compounds targeting multiple neurologic conditions.
Latest developments
2026-04-28 — PureTech Founded Entity Seaport Therapeutics Adds Intra-Cellular Therapies Founder and CEO, Dr. Sharon Mates, to its Board of Directors - BioSpace (biospace.com)
2025-11-06 — J&J brain drug acquired in $14.6B buyout cleared for broader use | BioPharma Dive (biopharmadive.com)
2025-04-03 — J&J acquires Intra-Cellular Therapies in multi-billion-dollar deal | ROI-NJ (roi-nj.com)
2025-04-02 — Johnson & Johnson Closes Landmark Intra-Cellular Therapies, Inc. Acquisition to Solidify Neuroscience Leadership (jnj.com)
2025-02-24 — Intra-Cellular Therapies Reports Fourth Quarter and Full-Year 2024 Financial Results - BioSpace (biospace.com)
2025-01-13 — Johnson & Johnson Strengthens Neuroscience Leadership with Acquisition of Intra-Cellular Therapies, Inc. (jnj.com)
Company details
Intra-Cellular Therapies was founded on research by Nobel laureate Dr. Paul Greengard and operates within the biopharmaceutical and healthcare sectors, with particular focus on psychiatric and neurodegenerative diseases. Intra-Cellular Therapies was founded in 2002, has an estimated 500-1,000 employees, and is headquartered in New York, New York.
Frequently asked questions
What does Intra-Cellular Therapies do?
Intra-Cellular Therapies is a biopharmaceutical company headquartered in New York, founded in 2002, with 500–1,000 employees and estimated revenue between $500 million and $1 billion. The company discovers and develops small-molecule treatments for central nervous system and neuropsychiatric disorders. Its approved product CAPLYTA treats schizophrenia and bipolar depression, while its pipeline addresses generalized anxiety disorder, Alzheimer's agitation, and Parkinson's disease. Johnson & Johnson acquired the company in 2025.
Where is Intra-Cellular Therapies headquartered?
Intra-Cellular Therapies is headquartered in New York, New York (430 East 29th Street, New York, New York, 10016).
When was Intra-Cellular Therapies founded?
Intra-Cellular Therapies was founded in 2002.
How big is Intra-Cellular Therapies?
Intra-Cellular Therapies has an estimated 500-1,000 employees, with revenue in the $500M-1B range (estimated).
Related suppliers
Explore other suppliers in the LightSource directory:
Last verified Nov 2026. Is this your company? Request a correction.
Location & contact
Evaluating suppliers like these?
This profile is part of a public-data sample of the full LightSource directory. Book a demo to see the full LightSource marketplace and supplier discovery platform — 1M+ credible suppliers, with AI-run sourcing events.
